The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 05, 2007
Filed:
Apr. 20, 2004
Paul Joseph Cox, Flemington, NJ (US);
Tahir Nadeem Majid, Hoboken, NJ (US);
Shelley Amendola, Bedminster, NJ (US);
Stephanie Daniele Deprets, Paris, FR;
Christoper David Edlin, Hitchin, GB;
Justine Yeun Quai Lai, Epping, GB;
Andrew David Morley, Macclesfield, GB;
Paul Joseph Cox, Flemington, NJ (US);
Tahir Nadeem Majid, Hoboken, NJ (US);
Shelley Amendola, Bedminster, NJ (US);
Stephanie Daniele Deprets, Paris, FR;
Christoper David Edlin, Hitchin, GB;
Justine Yeun Quai Lai, Epping, GB;
Andrew David Morley, Macclesfield, GB;
Aventis Pharma Limited, West Malling, GB;
Abstract
Chemical compositions containing physiologically active compounds of general formula (I): wherein Ris aryl or heteroaryl; Rrepresents hydrogen, acyl, cyano, halo, lower alkenyl or lower alkyl optionally substituted by a substituent selected from cyano, heteroaryl, heterocycloalkyl, -ZR, —C(═O)—NYY, —COR, —NYY, —N(R)—C(═O)—R, —N(R)—C(═O)—NYY, —N(R)—C(═O)—OR, —N(R)—SO—R, —N(R)—SO—NYYand one or more halogen atoms; Rrepresents hydrogen, aryl, cyano, halo, heteroaryl, lower alkyl, —C(═O)—ORor —C(═O)—NYY; and Xrepresents N, CH, C-halo, C—CN, C—R, C—NYY, C—OH, C-ZR, C—C(═O)—OR, C—C(═O)—NYY, C—N(R)—C(═O)—R, C—SO—NYY, C—N(R)—SO—R, C-alkenyl, C-alkynyl or C—NO; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit protein kinases.